Pipeline
Shattuck Labs is advancing a pipeline of novel biologic therapies designed to block the TL1A/DR3 pathway, a key driver of inflammation and immune dysregulation. Our lead program, SL-325, is a first-in-class DR3 blocking antibody engineered for exceptional potency, selectivity, and safety through a Fc-silenced antibody design. Additional preclinical programs, including SL-425 and bispecific DR3 blocking antibodies, aim to expand therapeutic potential across autoimmune and inflammatory diseases.
Shattuck’s Pipeline Targets the TL1A/DR3 Pathway
Shattuck’s lead DR3 blocking antibody, SL-325, was well tolerated in a Phase 1 clinical trial, and demonstrated potent and durable inhibition of TL1A binding to DR3 at low doses. Importantly, SL-325 has the potential to provide prolonged and accumulating clinical benefit to patients due to a potentially best-in-mechanism immunogenicity profile.
Developing potential first-in-class DR3 monospecific and bispecific antibodies
*SL-325 is intended for development across IBD, including both Crohn's disease and ulcerative colitis.